Welcome to our dedicated page for Bicycle Therapeutics news (Ticker: BCYC), a resource for investors and traders seeking the latest updates and insights on Bicycle Therapeutics stock.
Bicycle Therapeutics plc (NASDAQ: BCYC) is a clinical-stage pharmaceutical company developing Bicycle molecules, Bicycle Drug Conjugates (BDC) and Bicycle Radioconjugates (BRC) for oncology indications. News about BCYC often centers on progress across its clinical pipeline, strategic collaborations, and financial updates that shape the company’s development plans.
Investors and observers following BCYC news can expect regular updates on clinical trials such as the Duravelo-1 Phase 1 study, the Duravelo-2 Phase 2/3 pivotal trial in metastatic urothelial cancer, and the Duravelo-3 and Duravelo-4 Phase 1/2 studies in Nectin-4–amplified breast cancer and non-small cell lung cancer. The company also reports on data presentations at major scientific meetings, including imaging and clinical data for BRC molecules targeting EphA2 and MT1-MMP.
Company news also covers strategic partnerships, including long-term arrangements with the UK Nuclear Decommissioning Authority, the United Kingdom National Nuclear Laboratory, and SpectronRx to support an end-to-end 212Pb radiopharmaceutical supply chain. Additional announcements highlight Board of Directors changes, formation and expansion of the Research and Innovation Advisory Board, and inducement grants to new employees under the 2024 Inducement Plan.
On this BCYC news page, readers can track press releases on quarterly financial results, regulatory interactions related to zelenectide pevedotin’s potential approval pathway, and anticipated milestones such as dose selection decisions and data disclosures. For those researching Bicycle Therapeutics stock, this news feed provides a centralized view of the company’s operational, clinical, and corporate developments over time.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Bicycle Therapeutics plc (NASDAQ: BCYC) has announced its participation in the 2023 American Association for Cancer Research (AACR) Annual Meeting, scheduled from April 14-19, 2023 in Orlando, FL. The company will present four posters highlighting its innovative bicyclic peptide technology aimed at enhancing cancer treatment.
The presentations include:
- NK-TICA™ Agonist - Modulation of natural killer cell immune response on April 17.
- In Vivo Models for NK-TICA™ - Evaluation of a novel immune cell agonist on April 17.
- BT7455 - Anti-tumor efficacy study on April 17.
- BT7480 - Phase 1/2 study on April 18.
Further details will be available post-presentation on bicycletherapeutics.com.
ResearchAndMarkets.com has released the report "Global Genetic Disorders Partnering 2016-2023," providing a comprehensive overview of genetic disorder deals signed worldwide since 2016. The report captures key aspects including deal trends, financial terms, and the most active dealmakers in the biopharma industry. It includes detailed analyses of deal structures, contract documents, and financial metrics, such as headline values, upfront payments, and royalty rates. Covering multiple genetic disorders like Cystic Fibrosis and Huntington's Disease, this report aims to be an essential resource for stakeholders in genetic disorder collaborations.